U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541781) titled 'Sitagliptin in Recurrent/Progressive Grade 4 Glioma' on April 10.
Brief Summary: Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Study Start Date: May 31
Study Type: INTERVENTIONAL
Condition:
Glioma
Glioblastoma
Recurrent Glioma
Recurrent Glioblastoma
Grade 4 Malignant Glioma of Brain (Disorder)
Intervention:
DRUG: Sitagliptin
Sitagliptin, PO dose to be determined by Phase I dose de...